Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry

Biologic and targeted synthetic disease-modifying antirheumatic drugs (ts/bDMARDs) play a pivotal role in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Persistence of therapy provides an index of a drug’s overall effectiveness. The objective...

Descripción completa

Detalles Bibliográficos
Autores principales: Prior-Español, A., Sánchez-Piedra, C., Campos, J., Manero, F. J., Pérez-García, C., Bohórquez, C., Busquets-Pérez, N., Blanco-Madrigal, J. M., Díaz-Torne, C., Sánchez-Alonso, F., Mateo, L., Holgado-Pérez, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159943/
https://www.ncbi.nlm.nih.gov/pubmed/34045525
http://dx.doi.org/10.1038/s41598-021-90442-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159943/
https://www.ncbi.nlm.nih.gov/pubmed/34045525
http://dx.doi.org/10.1038/s41598-021-90442-w

Ejemplares similares